Your browser doesn't support javascript.
loading
Clinicopathological and Molecular Characteristics of Pleomorphic Invasive Lobular Carcinoma.
Segar, Jennifer M; Pandey, Ritu; Farr, Kiah J; Nagle, Raymond; LeBeau, Lauren; Gonzalez, Victor J; Chalasani, Pavani.
Afiliação
  • Segar JM; University of Arizona Cancer Center, Tucson, Arizona 85719, USA.
  • Pandey R; Department of Medicine, University of Arizona, Tucson, Arizona 85721, USA.
  • Farr KJ; University of Arizona Cancer Center, Tucson, Arizona 85719, USA.
  • Nagle R; College of Medicine, University of Arizona, Tucson, Arizona 85721, USA.
  • LeBeau L; University of Arizona Cancer Center, Tucson, Arizona 85719, USA.
  • Gonzalez VJ; Department of Pathology, University of Arizona, Tucson, Arizona 85721, USA.
  • Chalasani P; Department of Radiation Oncology, University of Arizona, Tucson, Arizona 85721, USA.
Int J Breast Cancer ; 2020: 8816824, 2020.
Article em En | MEDLINE | ID: mdl-33299611
ABSTRACT
Pleomorphic invasive lobular carcinoma (PILC) is a distinct morphological and biologically aggressive variant of invasive lobular carcinoma (ILC). We hypothesized that was due to de novo activation of PI3K/Akt/mTOR pathway in PILC resulting in higher proliferation rate and markers of cell cycle activation. We identified PILC and ILC tumors and tested for PI3K/Akt/mTOR pathway activation by immunohistochemistry (PTEN and pS6K1) and gene expression analysis (by Nanostring nCounter system). Proliferation index (Ki67) was elevated in 85% of PILCs compared to 20% of ILCs (p < 0.007). PTEN expression was high in all while pS6K1 was high in 8/9 PILCs compared to 3/9 ILCs (p < 0.007). Gene expression analysis shows that PILCs have overexpression of genes involved in cell cycle proliferation, cellular proliferation, DNA damage, and repair genes but no difference in PI3K/Akt/mTOR pathway genes. PILCs are a biologically distinct group of ILC, and clinicopathological characteristics suggest they would have a more clinically aggressive behavior. In addition, our results indicate that PI3k/Akt/mTOR pathway and cell cycle proliferation are activated in majority of these tumors. Further studies are needed to investigate these mechanisms as there are approved therapies available that may benefit PILCs.

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Ano de publicação: 2020 Tipo de documento: Article